Showing 7,221 - 7,240 results of 18,566 for search 'significantly ((((((we decrease) OR (linear decrease))) OR (a decrease))) OR (mean decrease))', query time: 0.50s Refine Results
  1. 7221

    Table 1_A study of the adjunctive therapeutic effects of a 3-week bamboo forest therapy on chronic diseases in the elderly.docx by Jing He (58446)

    Published 2025
    “…Diabetic participants showed significant decreases in fasting and pre-bedtime blood glucose levels (p < 0.001), along with reduced blood glucose fluctuations post-meal. …”
  2. 7222

    Participants’ view of the virtual environment. by Stephen H. Fairclough (7156868)

    Published 2024
    “…The current study will explore distortions in the perception of passage of time when threat is simulated using virtual reality (VR). 44 participants negotiated a large (13.6 × 8.4 m) virtual environment designed to maximise the realism of a physical threat by exposing participants to a virtual height of 200m. …”
  3. 7223

    Risk of bias across 22 included studie. by Kuo-Chuan Hung (8587392)

    Published 2024
    “…Trial sequential analysis (TSA) was conducted to validate the reliability.</p><p>Results</p><p>A meta-analysis of 22 RCTs (n = 3,463) showed that ketamine/esketamine significantly decreased PPD risk at 1- (risk ratio [RR], 0.41; 95% confidence interval [CI], 0.3–0.57) and 4–6-week (RR, 0.47; 95%CI, 0.35–0.63) follow-ups. …”
  4. 7224

    An overview of the selection process for studies. by Kuo-Chuan Hung (8587392)

    Published 2024
    “…Trial sequential analysis (TSA) was conducted to validate the reliability.</p><p>Results</p><p>A meta-analysis of 22 RCTs (n = 3,463) showed that ketamine/esketamine significantly decreased PPD risk at 1- (risk ratio [RR], 0.41; 95% confidence interval [CI], 0.3–0.57) and 4–6-week (RR, 0.47; 95%CI, 0.35–0.63) follow-ups. …”
  5. 7225

    Characteristics of studies (<i>n</i> = 22). by Kuo-Chuan Hung (8587392)

    Published 2024
    “…Trial sequential analysis (TSA) was conducted to validate the reliability.</p><p>Results</p><p>A meta-analysis of 22 RCTs (n = 3,463) showed that ketamine/esketamine significantly decreased PPD risk at 1- (risk ratio [RR], 0.41; 95% confidence interval [CI], 0.3–0.57) and 4–6-week (RR, 0.47; 95%CI, 0.35–0.63) follow-ups. …”
  6. 7226

    Data Sheet 1_Depositional model of a bioherm based on factor analysis: a case study in Western Beijing, China.docx by Hao Cheng (103394)

    Published 2024
    “…<p>As an important type of microbial carbonate, the study of bioherm sedimentary models is of great significance to the exploration and development of carbonate rock. …”
  7. 7227

    Data for faba bean. by Beamlaku Alemayehu (20648920)

    Published 2025
    “…The soil analysis result indicated that vermicompost and lime significantly increased soil pH and decreased exchangeable acidity. …”
  8. 7228

    Selected soil chemical properties after harvest. by Beamlaku Alemayehu (20648920)

    Published 2025
    “…The soil analysis result indicated that vermicompost and lime significantly increased soil pH and decreased exchangeable acidity. …”
  9. 7229

    Partial budget analysis. by Beamlaku Alemayehu (20648920)

    Published 2025
    “…The soil analysis result indicated that vermicompost and lime significantly increased soil pH and decreased exchangeable acidity. …”
  10. 7230

    Table 1_A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptors.docx by Paolo Romania (399007)

    Published 2025
    “…PLAC1 and DSG2 expression in healthy tissues and NK cells was obtained from the HPA database and a GEO dataset.</p>Results<p>We identified ten candidate genes whose downregulation in K562 cells decreased NK cell-mediated cytotoxicity to levels comparable to silencing the MICA gene. …”
  11. 7231

    Image 3_A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptors.jpg by Paolo Romania (399007)

    Published 2025
    “…PLAC1 and DSG2 expression in healthy tissues and NK cells was obtained from the HPA database and a GEO dataset.</p>Results<p>We identified ten candidate genes whose downregulation in K562 cells decreased NK cell-mediated cytotoxicity to levels comparable to silencing the MICA gene. …”
  12. 7232

    Image 1_A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptors.jpg by Paolo Romania (399007)

    Published 2025
    “…PLAC1 and DSG2 expression in healthy tissues and NK cells was obtained from the HPA database and a GEO dataset.</p>Results<p>We identified ten candidate genes whose downregulation in K562 cells decreased NK cell-mediated cytotoxicity to levels comparable to silencing the MICA gene. …”
  13. 7233

    Image 4_A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptors.jpg by Paolo Romania (399007)

    Published 2025
    “…PLAC1 and DSG2 expression in healthy tissues and NK cells was obtained from the HPA database and a GEO dataset.</p>Results<p>We identified ten candidate genes whose downregulation in K562 cells decreased NK cell-mediated cytotoxicity to levels comparable to silencing the MICA gene. …”
  14. 7234

    Table 2_A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptors.docx by Paolo Romania (399007)

    Published 2025
    “…PLAC1 and DSG2 expression in healthy tissues and NK cells was obtained from the HPA database and a GEO dataset.</p>Results<p>We identified ten candidate genes whose downregulation in K562 cells decreased NK cell-mediated cytotoxicity to levels comparable to silencing the MICA gene. …”
  15. 7235

    Image 2_A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptors.jpg by Paolo Romania (399007)

    Published 2025
    “…PLAC1 and DSG2 expression in healthy tissues and NK cells was obtained from the HPA database and a GEO dataset.</p>Results<p>We identified ten candidate genes whose downregulation in K562 cells decreased NK cell-mediated cytotoxicity to levels comparable to silencing the MICA gene. …”
  16. 7236

    Dynamic Regulation of Proton and Water Transport through an Acylhydrazone-Based Photoresponsive Channel by Paras Wanjari (22259362)

    Published 2025
    “…The compounds demonstrated significant proton transport when combined with valinomycin, indicating transmembrane proton transport for <b>1a</b>–<b>c</b>. …”
  17. 7237

    Presentation 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
  18. 7238

    Presentation 3_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
  19. 7239

    Data Sheet 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
  20. 7240

    Data Sheet 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”